Complete financial analysis of Taiwan Advanced Nanotech Inc. (6797.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taiwan Advanced Nanotech Inc., a leading company in the Healthcare industry within the Healthcare sector.
- Sinotruk Jinan Truck Co., Ltd. (000951.SZ) Income Statement Analysis – Financial Results
- International Business Settlement Holdings Limited (0147.HK) Income Statement Analysis – Financial Results
- AVTECH Sweden AB (publ) (AVT-B.ST) Income Statement Analysis – Financial Results
- Juniper II Corp. (JUN-WT) Income Statement Analysis – Financial Results
- Maithan Alloys Limited (MAITHANALL.BO) Income Statement Analysis – Financial Results
Taiwan Advanced Nanotech Inc. (6797.TWO)
About Taiwan Advanced Nanotech Inc.
Taiwan Advanced Nanotech Inc. designs and manufactures products for nucleic acid purification. The company's products include reagent kits, which are used in DNA/RNA extractions from samples of blood, cell, tissue, plant, bacteria, virus, etc.; magnetic nanoparticles, including super-paramagnetic iron oxide and ultra small super-paramagnetic iron oxide for molecular biology applications; automated extraction instruments; and consumables, such as spin tips and deep well plates. It offers its products to disease control centers, testing institutions, hospitals, and other related facilities. The company was founded in 2004 and is based in Taoyuan, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 245.61M | 1.33B | 1.93B | 1.72B | 113.96M |
| Cost of Revenue | 276.72M | 676.86M | 861.06M | 761.02M | 89.30M |
| Gross Profit | -31.11M | 649.68M | 1.07B | 958.06M | 24.66M |
| Gross Profit Ratio | -12.67% | 48.98% | 55.35% | 55.73% | 21.64% |
| Research & Development | 82.99M | 108.56M | 82.21M | 42.58M | 23.96M |
| General & Administrative | 106.76M | 146.08M | 126.74M | 71.43M | 0.00 |
| Selling & Marketing | 40.56M | 50.97M | 60.03M | 47.21M | 0.00 |
| SG&A | 147.29M | 197.05M | 186.77M | 118.64M | 46.26M |
| Other Expenses | 0.00 | 104.65M | -9.18M | -24.60M | 0.00 |
| Operating Expenses | 230.28M | 305.61M | 268.98M | 161.21M | 70.22M |
| Cost & Expenses | 507.00M | 982.47M | 1.13B | 922.23M | 159.52M |
| Interest Income | 32.70M | 17.58M | 5.29M | 1.07M | 707.00K |
| Interest Expense | 8.75M | 5.55M | 5.66M | 1.03M | 295.00K |
| Depreciation & Amortization | 120.67M | 111.15M | 85.02M | 32.82M | 14.18M |
| EBITDA | -114.06M | 577.45M | 879.49M | 806.14M | -30.30M |
| EBITDA Ratio | -46.44% | 43.53% | 45.61% | 46.89% | -27.54% |
| Operating Income | -261.39M | 466.30M | 794.47M | 773.32M | -45.56M |
| Operating Income Ratio | -106.42% | 35.15% | 41.20% | 44.98% | -39.98% |
| Total Other Income/Expenses | 17.91M | -5.60M | -7.06M | -23.74M | 793.00K |
| Income Before Tax | -243.48M | 460.70M | 791.29M | 773.10M | -44.77M |
| Income Before Tax Ratio | -99.13% | 34.73% | 41.03% | 44.97% | -39.28% |
| Income Tax Expense | -5.49M | 103.41M | 165.23M | 154.92M | -8.17M |
| Net Income | -208.19M | 326.01M | 626.04M | 618.19M | -36.60M |
| Net Income Ratio | -84.76% | 24.58% | 32.46% | 35.96% | -32.12% |
| EPS | -6.83 | 10.81 | 20.77 | 22.78 | -1.43 |
| EPS Diluted | -6.83 | 10.55 | 19.71 | 21.37 | -1.43 |
| Weighted Avg Shares Out | 30.49M | 30.15M | 30.14M | 27.13M | 25.67M |
| Weighted Avg Shares Out (Dil) | 30.49M | 30.89M | 31.76M | 28.93M | 25.67M |
Source: https://incomestatements.info
Category: Stock Reports